Barold S S, Wyndham C R, Kappenberger L L, Abinader E G, Griffin J C, Falkoff M D
Ann Intern Med. 1987 Aug;107(2):144-9. doi: 10.7326/0003-4819-107-2-144.
Five patients with drug-resistant paroxysmal atrial flutter received permanent burst atrial pacemakers for the treatment of tachycardia. All patients had extensive electrophysiologic evaluations to determine the safety and efficacy of atrial pacing. The absence of prolonged spontaneous or electrically induced atrial fibrillation was also documented in all patients. Three pulse generators were patient activated (nonautomatic) and two were multiprogrammable and automatic. The atrial pacemakers terminated many attacks of paroxysmal atrial flutter safely and reliably in a follow-up period ranging from 24 to 60 months (average, 42). No major complications developed. In four patients, concomitant drug therapy was necessary, although to a lesser degree, to reduce the frequency of attacks and the ventricular rate. Our study documents the long-term efficacy and low risk associated with permanent-burst atrial pacing in the treatment of drug-refractory paroxysmal atrial flutter in selected patients.
5例耐药性阵发性心房扑动患者接受了永久性短阵心房起搏器治疗心动过速。所有患者均进行了广泛的电生理评估，以确定心房起搏的安全性和有效性。所有患者均记录未出现长时间的自发性或电诱发心房颤动。3台脉冲发生器由患者启动（非自动），2台为多程控和自动型。在24至60个月（平均42个月）的随访期内，心房起搏器安全可靠地终止了许多阵发性心房扑动发作。未发生重大并发症。4例患者需要联合药物治疗，尽管程度较轻，以减少发作频率和心室率。我们的研究证明了永久性短阵心房起搏治疗特定患者耐药性阵发性心房扑动的长期疗效和低风险。
